ArticleFrontiers in veterinary science2025
Isolation and characterization of canine adenovirus type 2 (CAV-HN45) and its selective infection of human cervical cancer cells with preliminary oncolytic potential.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Canine adenovirus type 2 (CAdV-2) infects the respiratory tissues of dogs and induces canine infectious laryngotracheitis. CAdV-2 has a high incidence of infection and is easily co-infected with other viruses. Moreover, CAdV-2 is a mammalian adenovirus with characteristics similar to those of Human Adenovirus Type 5 (HAdV-5), making it a promising candidate for recombinant vaccine development and gene therapy applications. In this study, we isolated and identified a CAdV-2 strain (CAV-HN45) and investigated its growth characteristics and viral tropism by evaluating its infection efficiency in various cell lines. Our findings demonstrate that CAV-HN45 can effectively infect cells of swine, canine, and human origin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.